MedTrace Logo

Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors

NCT00579254 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the administration of the amlodipine/atorvastatin single pill to be appropriate

Conditions

  • Hypertension and Cardiovascular Risk Factors

Interventions

DRUG

CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)

Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00579254 on ClinicalTrials.gov